Exicure, Inc. (XCUR) announced today that the results of its Phase 2 study of burixafor (GPC‑100/TG‑0054), a CXCR4 antagonist, have been published in the journal Annals of Hematology.
The 12‑patient, multi‑center, open‑label study evaluated burixafor in combination with granulocyte colony‑stimulating factor (G‑CSF) in patients with multiple myeloma, non‑Hodgkin’s lymphoma, and Hodgkin disease undergoing autologous stem‑cell transplantation. Eleven of the 12 participants (92%) met the primary endpoint of collecting ≥5.0 × 10⁶ CD34⁺ cells/kg within two leukapheresis sessions, with six patients achieving the target in a single session.
The study also reported rapid mobilization kinetics, with peak CD34⁺ cell levels occurring within one hour of burixafor administration—substantially faster than existing CXCR4 inhibitors that peak 10–14 hours after dosing. Burixafor was well tolerated, with only two low‑grade, treatment‑related adverse events reported. The publication highlights the drug’s potential to simplify transplant logistics, reduce hospital resource utilization, and support emerging gene‑therapy workflows.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.